Kruti Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kruti Patel has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Leonard Jeff Harris
Oncology Division, Department of Medicine, University of Tennessee Health Sciences Center, Memphis, TN 38103, USA
2 shared publications - Michael G. Martin
WEST Cancer Center and Research Institute, Memphis, USA
2 shared publications Alva Weir
The University of Tennessee Health Science Center, Memphis, TN
1 shared publicationAnna-Carson Rimer Uhelski
Johns Hopkins University, Baltimore, MD
1 shared publication- Ari M. Vanderwalde
Caris Life Sciences, Phoenix, AZ 85040, USA
1 shared publication - Ayesha Mukhopadhyay
School of Public Health, University of Memphis, Memphis, TN, USA
1 shared publication
Latest Publications
- 29 November 2023
- Published by Wiley in European Journal of Haematology
- Vol. 112 (3) , 466-474
Hydroxyurea at escalated dose versus fixed low‐dose hydroxyurea in adults with sickle cell disease
- 29 November 2023
- Published by Wiley in European Journal of Haematology
- Vol. 112 (3) , 466-474
Hydroxyurea at escalated dose versus fixed low‐dose hydroxyurea in adults with sickle cell disease
- Open Access
- 5 June 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (6) , 518
Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
Precision medicine is essential for the modern care of a patient with cancer. Comprehensive molecular profiling of the tumor itself is necessary to determine the presence or absence of certain targetable abnormalities or biomarkers. In particular, lung cancer is a disease for which targetable genomic alterations will soon guide therapy in the majority of cases. In this comprehensive review of solid tumor-based biomarkers, we describe the genomic alterations for which targeted agents have been approved by the United States Food and Drug Administration (FDA). While focusing on alterations leading to approvals in a tumor-agnostic fashion (MSI-h, TMB-h, NTRK) and on those alterations with approvals in multiple malignancies (BRAF, ERBB2, RET, BRCA, PD-L1), we also describe several biomarkers or indications that are likely to lead to an approved drug in the near future (e.g., KRAS G12C, PD-L1 amplification, HER2 overexpression in colon cancer, HER2 mutations in lung cancer). Finally, we detail the current landscape of additional actionable alterations (EGFR, ALK, ROS1, MET) in lung cancer, a biomarker-rich malignancy that has greatly benefitted from the precision oncology revolution.
- 5 June 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (6) , 518
Open AccessPrecision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
Precision medicine is essential for the modern care of a patient with cancer. Comprehensive molecular profiling of the tumor itself is necessary to determine the presence or absence of certain targetable abnormalities or biomarkers. In particular, lung cancer is a disease for which targetable genomic alterations will soon guide therapy in the majority of cases. In this comprehensive review of solid tumor-based biomarkers, we describe the genomic alterations for which targeted agents have been approved by the United States Food and Drug Administration (FDA). While focusing on alterations leading to approvals in a tumor-agnostic fashion (MSI-h, TMB-h, NTRK) and on those alterations with approvals in multiple malignancies (BRAF, ERBB2, RET, BRCA, PD-L1), we also describe several biomarkers or indications that are likely to lead to an approved drug in the near future (e.g., KRAS G12C, PD-L1 amplification, HER2 overexpression in colon cancer, HER2 mutations in lung cancer). Finally, we detail the current landscape of additional actionable alterations (EGFR, ALK, ROS1, MET) in lung cancer, a biomarker-rich malignancy that has greatly benefitted from the precision oncology revolution.
- 20 March 2021
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 19 (3.5) , CLO21-023
CLO21-023: Antiviral Therapy Improves Hepatocellular Cancer Survival
"CLO21-023: Antiviral Therapy Improves Hepatocellular Cancer Survival" published on 17 Mar 2021 by National Comprehensive Cancer Network.
- 20 March 2021
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 19 (3.5) , CLO21-023
CLO21-023: Antiviral Therapy Improves Hepatocellular Cancer Survival
"CLO21-023: Antiviral Therapy Improves Hepatocellular Cancer Survival" published on 17 Mar 2021 by National Comprehensive Cancer Network.
- Open Access
- 13 November 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (22) , 8553
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies of heavily pre-treated patients with prolonged remissions achieved in some patients. Anti-CD19 CAR (chimeric antigen receptor) T cells are potentially curative in the 3rd line and beyond setting and are under investigation in earlier lines of therapy. Antibody-drug conjugates (ADC’s) such as polatuzumab vedotin targeting the pan-B-cell marker CD79b has proven effectiveness in multiply-relapsed DLBCL patients. Tafasitamab (MOR208) is an anti-CD19 monoclonal antibody producing prolonged remissions when combined with Lenalidomide (LEN) in patients who were not candidates for salvage chemotherapy or autologous stem cell transplant. Selinexor, an oral, small-molecule selective inhibitor of XPO1-mediated nuclear export (SINE), demonstrated prolonged activity against heavily-pretreated DLBCL without cumulative toxicity and is being investigated as part of an oral, chemotherapy-free regimen for relapsed aggressive lymphoma. This article reviews current strategies and novel therapies for relapsed/refractory DLBCL.
- 13 November 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (22) , 8553
Open AccessNovel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies of heavily pre-treated patients with prolonged remissions achieved in some patients. Anti-CD19 CAR (chimeric antigen receptor) T cells are potentially curative in the 3rd line and beyond setting and are under investigation in earlier lines of therapy. Antibody-drug conjugates (ADC’s) such as polatuzumab vedotin targeting the pan-B-cell marker CD79b has proven effectiveness in multiply-relapsed DLBCL patients. Tafasitamab (MOR208) is an anti-CD19 monoclonal antibody producing prolonged remissions when combined with Lenalidomide (LEN) in patients who were not candidates for salvage chemotherapy or autologous stem cell transplant. Selinexor, an oral, small-molecule selective inhibitor of XPO1-mediated nuclear export (SINE), demonstrated prolonged activity against heavily-pretreated DLBCL without cumulative toxicity and is being investigated as part of an oral, chemotherapy-free regimen for relapsed aggressive lymphoma. This article reviews current strategies and novel therapies for relapsed/refractory DLBCL.
- Open Access
- 29 September 2020
- Published by MDPI AG in Preprints.org
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies of heavily pre-treated patients with prolonged remissions achieved in some patients. Anti-CD19 CAR (chimeric antigen receptor) T cells are potentially curative in the 3rd line and beyond setting and are under investigation in earlier lines of therapy.1 Antibody-drug conjugates (ADC’s) such as polatuzumab vedotin targeting the pan-B-cell marker CD79b has proven effectiveness in multiply-relapsed DLBCL patients. Tafasitamab (MOR208) is an anti-CD19 monoclonal antibody producing prolonged remissions when combined with Lenalidomide in patients who were not candidates for salvage chemotherapy or autologous stem cell transplant. Selinexor, an oral, small-molecule selective inhibitor of XPO1-mediated nuclear export (SINE), demonstrated prolonged activity against heavily-pretreated DLBCL without cumulative toxicity and is being investigated as part of an oral, chemotherapy-free regimen for relapsed aggressive lymphoma. This article reviews current strategies and novel therapies for relapsed/refractory DLBCL.
- 29 September 2020
- Published by MDPI AG in Preprints.org
Open AccessNovel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies of heavily pre-treated patients with prolonged remissions achieved in some patients. Anti-CD19 CAR (chimeric antigen receptor) T cells are potentially curative in the 3rd line and beyond setting and are under investigation in earlier lines of therapy.1 Antibody-drug conjugates (ADC’s) such as polatuzumab vedotin targeting the pan-B-cell marker CD79b has proven effectiveness in multiply-relapsed DLBCL patients. Tafasitamab (MOR208) is an anti-CD19 monoclonal antibody producing prolonged remissions when combined with Lenalidomide in patients who were not candidates for salvage chemotherapy or autologous stem cell transplant. Selinexor, an oral, small-molecule selective inhibitor of XPO1-mediated nuclear export (SINE), demonstrated prolonged activity against heavily-pretreated DLBCL without cumulative toxicity and is being investigated as part of an oral, chemotherapy-free regimen for relapsed aggressive lymphoma. This article reviews current strategies and novel therapies for relapsed/refractory DLBCL.